Compugen Ltd (CGEN) Q3 2026 Earnings Call Highlights: Revenue Doubles as Gilead

Compugen Ltd (CGEN) reported Q3 2026 revenue of $3.8M, doubling from the prior year. CEO Dr. Eran Ophir discussed milestones with AstraZeneca and Gilead, including potential payments and clinical trial updates. The company has $117.5M in cash and expects funding into 2029. Clinical trials for COM701 and GS-0321 are progressing, with data expected in 2027.

Original reporting
Published Nov 12, 2026, 11:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Compugen Ltd (CGEN) Q3 2026 Earnings Call Highlights: Revenue Doubles as Gilead — source image
Decision brief

The 30-second read

$CGENNeutralMed
01

Why it matters

The disclosed cash position and pending milestone upside may prompt short‑term buying interest, but the small scale of revenue limits broader market impact.

02

Market read

Primary relevance to CGEN shareholders; limited spillover to biotech sector.

03

What to watch

Potential dilution from future financing rounds and execution risk of multiple Phase 3 trials could weigh on valuation.

Relevance 6/10Novelty 7/10Timing: post‑market today

Background

Compugen Ltd (NASDAQ: CGEN) held its Q3 2026 earnings call, providing updated financials and milestone payment details from its collaborations with Gilead and AstraZeneca.

Company-level read

Ticker impact

$CGENNeutralMedium confidence
Context

Q3 2026 earnings disclosed revenue of $3.8M, cash $117.5M, $90M received from Gilead and up to $758M in future milestones.

Expected impact

modest upside as investors price in cash runway and potential milestone payments

Evidence & confidence

The company reported doubled revenue YoY and a strong cash position, but no guidance; market reaction likely limited to short‑term speculative interest.

Market effects

Highlights ongoing partnership activity between biotech firms and big pharma (Gilead, AstraZeneca) in immuno‑oncology.

Limited to US biotech micro‑cap segment; no broader market effect.

Minimal, confined to niche oncology pipeline investors.

Counterpoint

Despite cash runway, the lack of near‑term data readouts and modest revenue suggest the stock may remain stagnant or face downside pressure.

Key entities

  • Compugen Ltd

    Biotech company developing immuno‑oncology therapies.

  • Gilead Sciences

    Pharma partner providing milestone payments to Compugen.

  • AstraZeneca

    Pharma partner with milestone agreements.

Related articles

$CGENMed

Compugen stock maintained at Buy by H.C. Wainwright, $4 target

H.C. Wainwright maintained a Buy rating and $4.00 target on Compugen (CGEN) after Q3 results. The stock trades at $2.09, up 9% in a week and 37% YTD. Compugen completed enrollment for its MAIA-ovarian study, with results expected by Q1 2027. Q3 revenue was $3.8M, up from $1.9M YoY but below estimates. The company expects sufficient cash to support operations through 2029.

$CGENMed

What Compugen (CGEN) Said on Its Q3 Earnings Call

Compugen (CGEN) reported Q3 revenue of $3.8M, up from $1.9M YoY. The company discussed milestones for its partnered programs with AstraZeneca and Gilead, including potential payments and royalties. Compugen also introduced UnigenX, an expansion of its AI-powered discovery engine. The net loss narrowed to $5.8M, or $0.06 per share, with $117.5M in cash equivalents.

$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

$DISMedAI 8/10

Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?

Disney (DIS) reported Q4 2026 revenue of $25.95B, up 16% YoY, with its Experiences segment hitting a record $10.1B. All units grew, with Experiences leading in operating income at $2.25B. Adjusted net income rose 56% to $3.35B, beating estimates. The company plans to invest $60B in Experiences over a decade, focusing on parks and cruises.

$GLADMed

Gladstone Capital (GLAD) Q4 2026 Earnings Call Transcript

Gladstone Capital (GLAD) reported Q4 2026 earnings with net interest margin at 8.2%. Fee income was below average, but incentive fee credit covered 100% of regular distributions. Net asset value declined to $20.77 per share due to unrealized depreciation and a supplemental distribution. Total investment income rose 11.7% for the year, covering distributions at 104.5%. The company discussed its investment strategy and credit management, highlighting its focus on the lower middle market.